Kundu Debanjan, Prerna Kumari, Chaurasia Rahul, Bharty Manoj Kumar, Dubey Vikash Kumar
1School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi, UP 221005 India.
2Department of Chemistry, Institute of Science, Banaras Hindu University, Varanasi, UP 221005 India.
3 Biotech. 2020 May;10(5):193. doi: 10.1007/s13205-020-2166-x. Epub 2020 Apr 4.
Protein aggregation, their mechanisms and trends in the field of neurodegenerative diseases is still far from completely being decoded. It is mainly attributed to the complexity surrounding the interaction between proteins which includes various regulatory mechanisms involved with the presentation of abnormal conditions. Although most proteins are functional in their soluble form, they have also been reported to convert themselves into insoluble aggregates under certain conditions naturally. Misfolded protein forms aggregates which are mostly unwanted by the cellular system and are mostly involved in various pathophysiologies including Alzheimer's, Type II Diabetes mellitus, Kurus's etc. Challenges lie in understanding the complex mechanism of protein misfolding and its correlation with clinical evidence. It is often understood that due to the slowness of the process and its association with ageing, timely intervention with drugs or preventive measures will play an essential role in lowering the rate of dementia causing diseases and associated ailments in the future. Today approximately more than 35 proteins have been identified capable of forming amyloids under defined conditions, and nearly all of them have been associated with disease outcomes. This review incorporates a major understanding from the history of diseases associated with protein misfolding, to the current state of neurodegenerative diseases globally, highlighting challenges in drug development and current state of research in a comprehensive manner in the field of protein misfolding diseases. There is increasing clinical association of protein misfolding with regards to amyloids compelling us to thread questions solved and further helping us design possible solutions by generating a pathway-based research on which future work in this field could be driven.
蛋白质聚集、其机制以及神经退行性疾病领域的发展趋势仍远未完全被破解。这主要归因于蛋白质之间相互作用的复杂性,其中包括与异常情况呈现相关的各种调节机制。尽管大多数蛋白质以可溶形式发挥功能,但也有报道称它们在某些条件下会自然转化为不溶性聚集体。错误折叠的蛋白质形成聚集体,而细胞系统大多不需要这些聚集体,并且它们大多与包括阿尔茨海默病、II型糖尿病、库鲁病等在内的各种病理生理学有关。挑战在于理解蛋白质错误折叠的复杂机制及其与临床证据的关联。人们通常认为,由于这个过程缓慢且与衰老相关,及时进行药物干预或采取预防措施对于降低未来导致痴呆的疾病和相关疾病的发病率将发挥至关重要的作用。如今,已鉴定出约35种以上的蛋白质能够在特定条件下形成淀粉样蛋白,并且几乎所有这些蛋白质都与疾病结果相关。本综述全面纳入了从与蛋白质错误折叠相关疾病的历史到全球神经退行性疾病现状的主要认识,突出了药物开发中的挑战以及蛋白质错误折叠疾病领域的当前研究状况。蛋白质错误折叠与淀粉样蛋白的临床关联日益增加,促使我们梳理已解决的问题,并通过开展基于途径的研究进一步帮助我们设计可能的解决方案,从而推动该领域未来的工作。